Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease
Brief Summary: RATIONALE: A PET scan may help doctors learn how the cancer responded to combination chemotherapy and whether radiation therapy is also required.

PURPOSE: This randomized phase III trial is studying giving a PET scan to see how well it works in deciding whether patients who have received combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma also need radiation therapy.


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II
B: Arm Label: Treatment (chemotherapy and F-18 PET/CT); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Doxorubicin Hydrochloride, Drug: Procarbazine Hydrochloride, Drug: Vinblastine Sulfate, Drug: Dacarbazine, Drug: Cyclophosphamide, Drug: Etoposide phosphate, Drug: prednisone, Drug: Radiation Therapy, Radiation: Fludeoxyglucose F-18, Procedure: computed tomography, Procedure: Positron Emission Tomography | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Procarbazine Hydrochloride; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Vinblastine Sulfate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Etoposide phosphate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Radiation Therapy; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: RADIATION; Name: Fludeoxyglucose F-18; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: PROCEDURE; Name: computed tomography; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: PROCEDURE; Name: Positron Emission Tomography; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT)
C: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: BEACOPP-14 chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Arm Label: BEACOPP-escalated chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm I, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I, Arm II, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy

Answer: A